Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $21.00 target price on the stock.

Other equities research analysts also recently issued research reports about the stock. B. Riley restated a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. HC Wainwright raised their price target on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Trading Down 5.2 %

NASDAQ:TRVI opened at $3.82 on Wednesday. Trevi Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.68. The stock’s 50 day simple moving average is $3.41 and its 200-day simple moving average is $3.14. The firm has a market cap of $293.63 million, a P/E ratio of -8.68 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the prior year, the business earned ($0.08) EPS. Research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Trevi Therapeutics in the 3rd quarter valued at approximately $63,000. Hsbc Holdings PLC acquired a new stake in Trevi Therapeutics during the 2nd quarter valued at $61,000. SG Americas Securities LLC purchased a new position in Trevi Therapeutics during the third quarter worth $78,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.